To gain an unbiased insight into the nature of the TR1-like CD4+ T-cell pools that arise in response to pMHCII-NP therapy, we profiled the transcriptome of murine type 1 diabetes (T1D)-relevant TR1-like CD4+ cells induced with BDC2.5 mi/IAg7-NP in vivo via RNAseq (twice a week for 5 weeks, starting at 10 weeks of age, when there is full-blown islet inflammation and most T1D-relevant autoantigenic specificities, including BDC2.5mi-specific CD4+ T cells, have undergone activation, a sine qua non requirement for pMHCII-NP-induced TR1 cell formation [11]). This evidence concerns the gene CD4 and type 1 diabetes mellitus.